Jack Khattar, Supernus CEO

Su­per­nus ex­pands its port­fo­lio of Parkin­son's drugs with a $400M+ buy­out

Su­per­nus is mark­ing its ex­pan­sion in­to the Parkin­son’s dis­ease are­na, strik­ing a deal to buy out Adamas Phar­ma­ceu­ti­cals in a deal worth more than $400 mil­lion.

A year af­ter swoop­ing in on its first Parkin­son’s ac­qui­si­tion, the two com­pa­nies an­nounced that they had reached an agree­ment for Su­per­nus to pay up to $9.10 per share in cash as part of the ac­qui­si­tion — close to $450 mil­lion.

“This ac­qui­si­tion rep­re­sents a sig­nif­i­cant step to fur­ther build a strong and di­verse Parkin­son’s dis­ease port­fo­lio, and aligns with our fo­cus of ac­quir­ing val­ue-en­hanc­ing, clin­i­cal­ly-dif­fer­en­ti­at­ed med­i­cines to treat CNS dis­eases,” said Su­per­nus CEO Jack Khat­tar in a state­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.